US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5646016A
· McCoy et al.
· 1997
[cited by applicant]
US 6099846A
· Levy et al.
· 2000
[cited by applicant]
US 20030100497A1
· Baker et al.
· 2003
[cited by applicant]
US 20050069549A1
· Herman
· 2005
[cited by applicant]
US 20060165713A1
· Gough et al.
· 2006
[cited by applicant]
US 20070298051A1
· Barouch et al.
· 2007
[cited by applicant]
US 20090010948A1
· Huang et al.
· 2009
[cited by applicant]
US 20090092578A1
· Su
· 2009
[cited by examiner]
US 20110263835A1
· Ting et al.
· 2011
[cited by applicant]
EP 920522
· 1998
[cited by applicant]
EP 3053592A1
· 2016
[cited by applicant]
JP 2013532971
· 2013
[cited by applicant]
WO WO9213955
· 1992
[cited by applicant]
WO WO0015663A1
· 2000
[cited by applicant]
WO WO0305992A1
· 2003
[cited by applicant]
WO WO2003059951
· 2003
[cited by applicant]
WO WO2004076489
· 2004
[cited by applicant]
WO WO2011161244A1
· 2011
[cited by applicant]
WO WO2019048936
· 2019
[cited by applicant]
Fredriksen and Bogen (Blood, 110: 1797-1805, 2007).
[cited by examiner]
Biragyn, Aiya et al., “Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity” Nature Biotechnology, 1999, pp. 253-258, vol. 17.
[cited by applicant]
Biragyn, Aiya et al., Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by Beta-Defensin 2 Science, 2002, pp. 1025-1029, vol. 298.
[cited by applicant]
Bogen, B., et al., “Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities,”
[cited by applicant]
Borysiewicz, L., et al., “A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,”
[cited by applicant]
Brunsvik, A et al., “Construction ofTetrabodies for Cancer Vaccines” The National Hospital, Oslo, NO, Abstract, 2002.
[cited by applicant]
Brunsvik, A. et al., “Vaccibodies: Future Vaccines for B Cell Lymphoma and Myeloma?” Institute of Immunology, Univ. of Oslo, Oslo National Hospital; Olso, NO, Abstract, 2003.
[cited by applicant]
Chen, Hsin-Wei et al., “Linkage ofCD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment” Cancer Immunol Immunother, 2002, pp. 341-348, vol. 51.
[cited by applicant]
Dennis, Carina, “Off by a whisker” Nature, 2006, pp. 739-741, vol. 442.
[cited by applicant]
Eisen, Herman N et al., “Lambda Chains and Genes in Inbred Mice” Annual Reviews Immunology, 1985, pp. 337-365 vol. 3.
[cited by applicant]
Eisen, Herman N. et al., “Mouse Myeloma Proteins with Antihapten Antibody Activity. The Protein Produced by Plasma Cell Tumor MOPC-315” Biochemistry, 1968, pp. 4126-4134, vol. 7, No. 1.
[cited by applicant]
Fredriksen, Agnete Brunsvik et al.,“DNA Vaccines Increase Immunogenicity of Idiotypic Tumor Antigen by Targeting Novel Fusion Proteins to Antigen-Presenting Cells” Molecular Therapy, 2006, pp. 776-785, vol. 13.
[cited by applicant]
Fredriksen, Agnete Brunsvik and Bogen, Bjarne, “Chemokine-idiotype Fusion DNA Vaccines are Potentiated by Bivalency and Xenogeneic Sequences” Blood, 2007, pp. 1797-1805, vol. 110.
[cited by applicant]
Hoogenboom, Rennie R .: , “Mix and match: Building manifold binding sites” Nature Biotechnology, 1997, pp. 125-226, vol. 15.
[cited by applicant]
Horwell, D. C., “The peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides,”
[cited by applicant]
Hu, Shi-zhen et al., “Minibody: A Novel Engineered Anti-Carcinoembryotic Antigen Antibody Fragment (Single-Chain Fv-CH3), Which Exhibits Rapid, High-Level Targeting of Xenografts” Cancer Research, 1996, pp. 3055-3061, v…
[cited by applicant]
Huang, Hsing-I et al., “Improved immonugenicity of a self tumor antigen by covalent linkage to CD40 ligand” International Journal of Cancer, 2004, pp. 696-703, vol. 108.
[cited by applicant]
Huang, Tzu-Hsuan et al., “Enhanced anti tumor immunity by fusion of CTLA-4 to a self tumor antigen” Blood, 2000, pp. 3663-3670, vol. 96, No. 12.
[cited by applicant]
Kriangkum, J., et al., “Bispecific and bifunctional single chain recombinant antibodies,” Biomolecular.Engineering,.2001, p. 31-40, vol. 18(2).
[cited by applicant]
Kutzler, M. A., and Weiner, D. B., “DNA Vaccines: Ready for Prime Time?”
[cited by applicant]
Lewis, Anne D. et al., “Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer” Journal of Virology, 2002, pp. 8769-8775, vol. 76, No. 17.
[cited by applicant]
Lunde E, et al., “Troybodies and Pepbodies” Biochemical Society Transactions, 2002, pp. 500-506, vol. 30, part 4.
[cited by applicant]
Lunde, Elin et al., “Troy-bodies': Recombinant Antibodies that Target T Cell Epitopes to Antigen Presenting Cells” International Reviews of Immunology, 2001, pp. 647-673, vol. 20.
[cited by applicant]
Macgregor, R. R., et al., “T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev,” AIDS, 2002, pp. 2137-2143, vol. 16(16).
[cited by applicant]
Menten, P., et al., “The LD78 isoform of MIP-la is the most potent CCR5 agonist and HIV-I-inhibiting chemokine,” The Journal of Clinical Investigation, 1999, pp. RI-R5, vol. 104(4).
[cited by applicant]
Noel, Daniele et al., “High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer” Human Gene Therapy, 2002, pp. 1483-1493, vol. 13.
[cited by applicant]
Øynebraten, I et al., “P19-39. Vaccibodies: a Novel Vaccine Strategy for HN that Target Viral Antigens to APC” Retrovilogy, Biomed Central Ltd., 2009.
[cited by applicant]
Plückthun, Andreas and Pack, Peter, “New protein engineering approaches to multivalent and bispecific antibody fragments” Immunotechnology, 1997, pp. 83-105, vol. 3.
[cited by applicant]
Proost Pet al., “Cleavage by CD26/dipeptidyl peptidase N converts the chemokine LD78beta into a Most Efficient Monocyte Attractant and CCRI Agonist” Blood, 2000.
[cited by applicant]
Rahman, F., et al., “Cellular and Humoral Immune Responses Induced by Intradermal or Intramuscular Vaccination With the Major Hepatitis B Surface Antigen,”
[cited by applicant]
Rochlitz, Christoph F ., “Gene Therapy of Cancer” Swiss Medicine Weekly, 2001, pp. 4-9, vol. 131.
[cited by applicant]
Ruffini, Pier Adelchi, et al., “Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines” Haematologica, 2002, pp. 989-1001, vol. 87.
[cited by applicant]
Ruffini, Pier Aldechi et al., “Human chemokine MIPlalpha increases efficiency of targeted DNA fusion vaccines” Vaccine, 2010, pp. 191-199, vol. 29.
[cited by applicant]
Schall, T., et al., “Human Macrophage Inflammatory Protein a (MIP-la) and MIP-1,B Chemokines Attract Distinct Populations of Lymphocytes,” J. Exp. Med., 1993, vol. 177, pp. 1821-1825.
[cited by applicant]
Schiavo, R., et al., “Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses,” Blood, 2006, vol. 107, pp. 4597-4605.
[cited by applicant]
Schjetne, Karoline W et al., “Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors” Journal of Immunology, 2007, pp. 4169-4176, vol. 178.
[cited by applicant]
Schulenburg et al., “Amino Acid Sequence of the Light Chain from a Mouse Myeloma Protein with Anti-Hapten Activity: Evidence for a Third Type of Light Chain” PNAS, 1971, pp. 2623-2626, vol. 68, No. 11.
[cited by applicant]
Simon, R. J., et al., “Peptoids: A modular approach to drug discovery,” Proceedings of the National Academy of Sciences of the United States of America, 1992, pp. 9367-9371, vol. 89(20).
[cited by applicant]
Slavin-Chiorini, Dale C et al., “Biologic Properties of a CH2 Domain-Deleted Recombinant Immunoglobulin” Internal Journal of Cancer, 1993, pp. 97-103, vol. 53.
[cited by applicant]
Snodgrass, H. R., et al., “Restricted a/ receptor gene usage of idiotype-specific major histocompatibility complex-restricted T cells: selection for CDR3-related sequences,”
[cited by applicant]
Stevenson et al., “DNA vaccines to attack cancer” PNAS, 2004, p. 14646-14652 vol. 101.
[cited by applicant]
Tang, DC., et al., “Genetic immunization is a simple method for eliciting an immune response,” Nature, 1992, pp. 152-154, vol. 356(6365).
[cited by applicant]
Tunheim, G., et al., “Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates,”
[cited by applicant]
Van Spriel, Annemiek B et al., “Immunotherapeutic perspective for bispecific antibodies” Immunology Today, 2000, pp. 391-396, vol. 21, No. 8.
[cited by applicant]
Verma, Inder M and Somia, Nikunj, “Gene Therapy—Promises, Problems, and Prospects” Nature, 1997, pp. 239-242, vol. 389.
[cited by applicant]
Vile, RG et al., “Cancer Gene Therapy: Hard Lessons and New Courses” Gene Therapy, 2000, pp. 2-8, vol. 7, Macmilan Publishers Ltd.
[cited by applicant]
Voskoglou-Nomikos, Theodora, “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models” Clinical Cancer Research, 2003, pp. 4227-4239, vol. 9.
[cited by applicant]
Wang, R., et al., Induction of Antigen-Specific Cytotoxis T Lymphocytes in Humans by a Malaria DNA Vaccine,
[cited by applicant]
Grodeland et al.: “Targeting of HA to chemokine receptors induces strong and cross-reactive T cell responses after DNA vaccination in pigs”
[cited by applicant]